Featured Clinical Trials

Hollings Cancer Center strives to bring its patients cutting edge cancer treatment options. Below is a listing of featured trials available at Hollings Cancer Center.

A Randomized Phase II Study of Perioperative mFolfirinox Versus Gemcitabine/Nab-paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
NCT02562716
PI: Ernest Camp
Study Coordinator: Alan Brisendine brisend@musc.edu 843-792-9007
A Phase II Study of ABC294640 in Patients with Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib
NCT02939807
PI: Carolyn Britten
Study Coordinator: Alan Brisendine brisend@musc.edu 843-792-9007
Phase 3 Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) utilizing BMS-936558 and BMS-734016 compounds
NCT02477826
PI: John Wrangle
Study Coordinator: Eleanor Hardy hardyel@musc.edu
A Phase 1b Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects with Advanced Malignancies
NCT02683395
PI: Carolyn Britten
Study Coordinator: Alan Brisendine brisend@musc.edu 843-792-9007
A Phase IB/II Study Of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT02523469
PI: John Wrangle
Study Coordinator: Stacey Coggins cogginss@musc.edu